In this article, we will look at August’s Top 10 traded U.S. stocks on Singapore’s POEMS trading platform, based on their gross market value traded. We hope this data will give you an overall macroeconomic view and provide insights on liquidity and consumer trend that affect these popular traded stocks.
We saw three U.S. major indexes: Dow Jones, S&P 500 and Nasdaq Composite continue to rise in the month of August. While Dow Jones Index was approximately 3% away from setting its new all-time high, both S&P 500 and Nasdaq Composite rose beyond 3,500 points and 12,000 mark respectively.
Without further ado, let’s countdown the list starting from the 10th position:
10th: Zoom Video Communications Inc (NASDAQ: ZM)
One of the rising stars amid the COVID-19 pandemic, Zoom Video finally made it to the top 10 list on POEMS. The stock’s price surpassed USD300 and soared more than 40% since its last quarterly earnings report.
Amidst the consistent surge in new COVID-19 cases, the usage of Zoom video remains high and looks set to become a permanent structural change. Investors’ focus will be on the company’s second quarter earnings release (released on 31 Aug) where it justifies whether its rise to stardom is sustainable. The consensus EPS forecast for the quarter is USD0.341.
9th: Alibaba Group Holding Ltd (NASDAQ: BABA)
China’s tech giant fell from its previous 6th spot in July, but still maintained its position as one of the most traded stocks on POEMS. Alibaba’s stock price has been consistently inching high and is now trading at near 52-weeks high level.
The consistent rise in the tech giant’s share price in August could be attributed by the IPO announcement of the much anticipated ANT Financial Group, which is an affiliate of Alibaba. The fintech company is looking to raise a record of USD30 billion shares in its planned IPO2.
This will certainly capture investors’ interest in Alibaba.
8th: Moderna Inc (NASDAQ: MRNA)
One of the forerunners in coming up with COVID-19 vaccine, Moderna has fallen off from its 4th position in July. The company’s share price in August was not encouraging when it plunged to USD64 on 31 August after hitting a record high at USD95 on 17 July.
Though the clinical trials for its COVID-19 vaccine candidate (Mrna-1273) is progressing well, the biotech company’s patents filed are probed by the U.S. Defense Department. The company is alleged to have failed to disclose USD25 million in government funding as required by federal law3.
7th: Sorrento Therapeutics Inc (NASDAQ: SRNE)
Another forerunner of the COVID-19 vaccine, Sorrento Therapeutics improved its standing among the top traded stocks on POEMS to the 7th spot. The biotech company sees the share price hit its record high of USD19.39 on 10 August before retracing back to USD8 level on 31 August.
The fall from its record high share price was mainly due to a controversial report published by Hindenburg Research with regards to the company’s COVID-19 diagnostic products, where it is believed to manipulate negatively on the company’s stock price4. Following that, U.S. Food and Drug Administration (FDA) also announced the emergency use authorisation of SalivaDirect COVID-10 diagnostic test developed by Yale University. This competes directly with Sorrento’s COVI-TRACE.
6th: Facebook Inc (NASDAQ: FB)
Facebook claims its 6th spot on the list in August. With NASDAQ surging to past record level, this tech giant is one of the tech leaders leading the way and trading at record levels. Facebook’s share price broke the USD300 price level on 26 August though it has since fallen to USD295.
The recent operational mistake of Facebook to remove a militia page puts the company in a vulnerable position especially so after the previous hate speech saga from U.S. President Donald Trump resulting in an advertisement boycott. This had happened when two people who were shot and killed during protests, following a white police officer’s shooting that left a black man, Jacob Blake Jr, paralysed. All eyes were on Facebook on its handling of this thorny situation5.
5th: Fastly Inc (NYSE: FSLY)
Fastly, a provider of edge cloud computing and content delivery network (CDN) climbed all the way from 10th spot in July to 5th this month. However, it was a roller coaster ride for Fastly’s share price. After hitting high at USD116 on 5 August, it took a fall to USD73 on 11 August before recovering to about USD94 towards the end of August.
The sink in share price was mainly due to the forward guidance during its earnings announcement where it fall short of lofty hopes. However, the management is still confident of the business growth for the remainder of 2020. On 27 August, Fastly announced its acquisition of Signal Sciences to enhance its cyber security’s solutions offering5.
4th: Apple Inc (NASDAQ: AAPL)
The popular maker of iPhone, Apple, finally made it to the list this month, occupying the 4th position. Its share price surpassed USD500 and is more than double as compared to March.
At the end of July, Apple announced its quarterly result which smashed analysts’ estimates and sent the stock soaring high. On the same day, Apple also announced a forward stock split of 4 for 1, which took effect on 31 August, the same day as Tesla. The shares soared higher and propelle Apple as the first U.S. company to surpass USD2 trillion market cap. In August 2018, Apple was the first U.S. company to hit USD1 trillion6. It only took Apple around two years to double its valuation.
3rd: Microsoft Corporation (NASDAQ: MSFT)
The tech giant took a step back this month but remained on the list’s the top 3. In comparison to other stocks on the list, the price movement of Microsoft is relatively stable in August with only about a fluctuation of +/- 5%.
The trading volume on Microsoft remained high mainly due to the news and rumours around its bidding on TikTok. The popular video application was forced to sell its U.S. business due to the privacy issues raised by the U.S. government. However, the deal remains uncertain as China has recently tightened their tech export rule7.
2nd: NIO Inc (NYSE: NIO)
A rival to Tesla, NIO together with recently listed Li Auto and XPeng, are competing against Tesla in China, the world’s largest electronic vehicle market. NIO climbed up one spot to second this month.
The stock crossed the USD20 mark, up almost 90% on 26 August. However, the share price took a dip upon announcement of its additional offering. NIO announced a secondary offering in August to seek additional funding of around USD1.4 – 1.7 billion8.
1st: Tesla Inc (NASDAQ: TSLA)
The month of August belongs to the electronic vehicle maker and leader, Tesla. Top on the list, its total value traded on POEMS is also higher than the previous month.
On 10 August, Tesla announced a forward split of 5 for 1 with effect on 31 August and the stocks spiked about 70%. In July, Tesla took over Toyota as the world’s largest car maker in term of market capitalisation and today, it is worth more than 2 times of Toyota9.
-  https://www.nasdaq.com/market-activity/stocks/zm/earnings#
-  https://asia.nikkei.com/Business/Companies/Alibaba-s-Ant-targets-largest-ever-30bn-IPO-report
-  https://www.ft.com/content/2be1f87e-9e96-4e23-9cc5-33ba35e50586
-  https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-take-action-against-hindenburg-research-statements
-  https://www.channelnewsasia.com/news/business/zuckerberg-says-facebook-s-failure-to-remove-militia-page-an–operational-mistake–13065294
-  https://www.cnbc.com/2020/08/19/apple-reaches-2-trillion-market-cap.html
-  https://www.theverge.com/2020/8/29/21406884/tiktok-china-tech-export-sale-microsoft-trump
-  https://www.nasdaq.com/articles/why-nios-%241.5-billion-stock-offering-is-bullish-2020-08-28
-  https://reneweconomy.com.au/tesla-worth-double-toyota-as-investors-look-to-massive-ev-battery-play-52786/
Important Information: This report is prepared and/or distributed by Phillip Securities Research Pte Ltd (“Phillip Securities Research”), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgement. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES Where the report contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.
If Distribution is to Australian Investors This report is produced by Phillip Securities Pte Ltd and is being distributed in Australia by Phillip Capital Limited (Australian Financial Services License No. 246827). This report contains general securities advice and does not take into account your personal objectives, situation and needs. Please read the Disclosures and Disclaimers set out above. By receiving or reading this report, you agree to be bound by the terms and limitations set out above. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.